证券代码：688180 证券简称：君实生物 公告编号：临 2023-072 上海君实生物医药科技股份有限公司 关于召开 2023 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2023 年 11 月 8 日（星期三）至 2023 年 11 月 14 日（星期 二）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮 箱 info@junshipharma.com 进行提问。上海君实生物医药科技股份有限公司（以 下简称"公司"）将在说明会上对投资者普遍关注的问题进行回答。 公司已于 2023 年 10 月 28 日在上海证券交易所网站（www.sse.com.cn）披 露公司 2023 年第三季度报告，为加强与投资者的深入交流，在上海证券交易所 的支持下，公司拟于 2023 年 11 月 15 日 9:00-10:00 召开 2023 年第三季度业绩说 明会，就投资者关心的问题进行交流。 三、参加人员 参加此次说明会人员包括：执行董事、总经理 NI ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2023年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海君實生物醫藥科技股份有限公司 呈交日期: 2023年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 | 01877 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 219,295,700 | RMB | | 1 RMB | | 219,295,700 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 219,295,700 | RMB | | 1 RMB | | 219,295,700 | | 2. 股份分類 | 普通股 | 股份類別 | A | | 於 ...

二、 回购方案的进展情况 证券代码：688180 证券简称：君实生物 公告编号：临 2023-071 上海君实生物医药科技股份有限公司 关于以集中竞价交易方式回购股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 截至2023年10月31日，上海君实生物医药科技股份有限公司（以下简称 "公司"）通过上海证券交易所交易系统以集中竞价交易方式已累计回购股份 559,711股，占公司总股本比例为0.0568%，回购成交的最高价为人民币40.49元/ 股，最低价为人民币37.91元/股，支付的资金总额为人民币21,928,547.45元（不含 印花税、交易佣金等交易费用）。 一、 回购股份的基本信息 2023年9月8日，公司召开第三届董事会第二十二次会议，审议通过了《关于 以集中竞价交易方式回购公司股份方案的议案》，同意公司以集中竞价交易方式 回购公司股份，回购资金总额不低于人民币3,000万元（含），不超过人民币6,000 万元（含）；回购价格不超过人民币58元/股（含）；回购期限自公司董事会审议 通 ...

证券代码：688180 证券简称：君实生物 上海君实生物医药科技股份有限公司 投资者关系活动记录表 □特定对象调研 □分析师会议 □媒体采访 业绩说明会 投资者关系活动 类别 □新闻发布会 □路演活动 □现场参观 □其他 参与单位名称 国盛证券、长江证券、海通证券、中信证券、东北证券、华安证券、申 万宏源证券、浙商证券、国金证券、兴业证券、国泰君安证券、建信基 金、中信建投、工银瑞信、建信养老、大家资产、诺安基金、源峰基 金、泰康基金、天弘基金、进门财经、百年保险资管、宏鼎投资、北京 汉和汉华资本管理有限公司、天治基金、东方证券资管、上海原泽私募 基金管理有限公司、上海盟洋投资管理有限公司、杭州巨子私募基金管 理有限公司、红土创新基金、理成资产、上海合道资产管理有限公司、 西藏合众易晟投资管理有限责任公司、恒越基金、宁波市浪石投资控股 有限公司、Atlantis Investment Management Group、太平资管、广东乐赢 私募基金管理有限公司、上海朴信投资管理有限公司、朱雀基金、上海 弘尚资产、博裕资本、中航基金、中信建投自营、上海保银私募基金管 理有限公司、仁布投资、华夏基金、混沌投资、碧 ...

美国商品名：LOQTORZI™ 申请事项：生物制品许可申请（Biologics License Application） 证券代码：688180 证券简称：君实生物 公告编号：临 2023-070 上海君实生物医药科技股份有限公司 自愿披露关于特瑞普利单抗获得 FDA 批准上市的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，上海君实生物医药科技股份有限公司（以下简称"公司"）的合作伙 伴 Coherus BioSciences, Inc.（以下简称"Coherus"）收到美国食品药品监督管理 局（以下简称"FDA"）的通知，特瑞普利单抗（美国商品名：LOQTORZI™）联 合顺铂/吉西他滨作为转移性或复发性局部晚期鼻咽癌成人患者的一线治疗，以 及作为单药治疗既往含铂治疗过程中或治疗后疾病进展的复发性、不可切除或转 移性鼻咽癌的成人患者的生物制品许可申请（Biologics License Application，以下 简称"BLA"）已获得批准，特瑞普利单抗成为美国首款且唯一获批用于鼻咽癌 治疗的药物，也是 ...

Financial Performance - Q3 2023 revenue reached ¥316,754,900.60, an increase of 16.31% year-over-year[4] - Net profit attributable to shareholders was -¥409,405,996.25, with a year-to-date loss of -¥1,406,818,402.73[4] - Basic and diluted earnings per share for the quarter were both -¥0.42, compared to -¥1.43 year-to-date[5] - Total revenue for the first three quarters of 2023 was ¥986,457,567.67, a decrease of 19.06% compared to ¥1,218,381,861.73 in the same period of 2022[15] - Net loss for the third quarter of 2023 was ¥1,555,128,891.35, compared to a net loss of ¥1,734,538,953.68 in the same quarter of 2022, showing an improvement[17] - The company reported a basic and diluted earnings per share of -¥1.43 for the third quarter of 2023, an improvement from -¥1.75 in the same quarter of 2022[18] Research and Development - Total R&D investment for the quarter was ¥322,027,822.49, a decrease of 43.89% year-over-year, representing 101.66% of revenue[5] - Research and development expenses for the first three quarters of 2023 amounted to ¥1,270,626,649.07, a decrease of 22.36% compared to ¥1,636,118,643.63 in 2022[15] - The company is advancing clinical trials for its first-in-human anti-tumor antibody, Tifcemalimab, in combination with Toripalimab for small cell lung cancer[12] - The company has received approval for the clinical trial application of a PD-1 and VEGF bispecific antibody, with the first patient dosing completed[12] Assets and Liabilities - Total assets at the end of the quarter were ¥11,587,144,221.39, down 7.73% from the end of the previous year[5] - The company's total equity decreased to ¥8,337,698,673.95 in 2023 from ¥9,776,460,263.22 in 2022, a decline of 14.73%[15] - Total liabilities increased to ¥3,249,445,547.44 in 2023 from ¥2,782,035,912.21 in 2022, reflecting a growth of 16.83%[15] - The company reported cash and cash equivalents of approximately RMB 4.17 billion as of September 30, 2023, down from RMB 6.03 billion at the end of 2022[14] - The total assets of the company decreased to approximately RMB 11.59 billion as of September 30, 2023, compared to RMB 12.56 billion at the end of 2022[14] Shareholder Information - The company had 32,991 common shareholders at the end of the reporting period[8] - The largest shareholder, HKSCC NOMINEES LIMITED, held 22.25% of shares, totaling 219,291,230 shares[8] Cash Flow - The company reported a net cash outflow from operating activities of -¥1,664,114,192.65 year-to-date[4] - The total cash inflow from operating activities was 1,236,480,347.79, while total cash outflow was 2,900,594,540.44, reflecting a challenging operational environment[19] - Cash inflow from financing activities amounted to 937,789,838.50, with cash outflow of 496,595,535.82, leading to a net cash flow from financing activities of 441,194,302.68[19] - The ending balance of cash and cash equivalents was 4,141,718,242.77, compared to 3,001,414,742.11 at the end of the previous year, showing an increase in liquidity[20] - The company experienced a foreign exchange impact on cash and cash equivalents amounting to 21,536,381.05, which affected the overall cash position[19] Sales Performance - Sales revenue from the drug Toripalimab (brand name: Tuoyi®) reached approximately RMB 668 million, an increase of about 29.7% year-on-year[12] - The company achieved a total revenue of approximately RMB 892 million for the year-to-date, representing a year-on-year growth of approximately 67.8%[12] Inventory and Receivables - The company reported accounts receivable of approximately RMB 366 million as of September 30, 2023, up from RMB 238 million at the end of 2022[14] - Inventory increased to approximately RMB 748 million as of September 30, 2023, compared to RMB 599 million at the end of 2022[14]

Financial Performance - The company's revenue for Q3 2023 was approximately ¥316.75 million, representing a year-on-year increase of 16.31%[4] - The net profit attributable to shareholders for Q3 2023 was approximately -¥409.41 million, with a year-to-date net profit of -¥1.41 billion, indicating a significant loss[4] - Basic and diluted earnings per share for Q3 2023 were both -¥0.42, compared to -¥1.43 in the same period last year[5] - Total operating revenue for the first three quarters of 2023 was RMB 986,457,567.67, a decrease of 19.06% compared to RMB 1,218,381,861.73 in the same period of 2022[16] - The net loss for the third quarter of 2023 was RMB 1,555,128,891.35, compared to a net loss of RMB 1,734,538,953.68 in the same quarter of 2022, indicating an improvement[19] - The total comprehensive loss for the third quarter of 2023 was RMB -1,605,861,657.78, compared to RMB -1,755,730,362.15 in the same quarter of 2022[19] Research and Development - Total R&D expenses for Q3 2023 amounted to approximately ¥322.03 million, a decrease of 43.89% year-on-year, and accounted for 101.66% of revenue, down 109.07 percentage points[5] - Research and development expenses for the first three quarters of 2023 amounted to RMB 1,270,626,649.07, a decrease of 22.36% compared to RMB 1,636,118,643.63 in 2022[16] - The company plans to continue focusing on research and development to enhance its product offerings and market position[16] - The company is advancing clinical trials for its first-in-human anti-tumor antibody, tifcemalimab, with approvals from both the FDA and the National Medical Products Administration[12] Assets and Liabilities - The total assets at the end of Q3 2023 were approximately ¥11.59 billion, a decrease of 7.73% compared to the end of the previous year[5] - The equity attributable to shareholders decreased by 14.96% year-on-year, amounting to approximately ¥8.06 billion[5] - Total liabilities as of the end of the third quarter of 2023 were RMB 3,249,445,547.44, an increase of 16.83% from RMB 2,782,035,912.21 at the end of 2022[18] - The total equity attributable to shareholders of the parent company decreased to RMB 8,064,611,883.59 from RMB 9,483,626,151.70 in the previous year, reflecting a decline of 14.93%[18] Cash Flow - The net cash flow from operating activities for the year-to-date was approximately -¥1.66 billion, indicating increased cash outflow compared to the previous period[7] - The net cash flow from operating activities for Q3 2023 was -1,664,114,192.65, compared to -1,117,489,221.19 in Q3 2022, indicating a decline in operational cash flow[21] - Total cash inflow from investment activities was 1,290,836,234.04, while cash outflow was 1,944,670,480.18, resulting in a net cash flow from investment activities of -653,834,246.14[21] - Cash inflow from financing activities amounted to 937,789,838.50, with cash outflow of 496,595,535.82, leading to a net cash flow from financing activities of 441,194,302.68[21] - The total cash inflow from operating activities was 1,236,480,347.79, while total cash outflow was 2,900,594,540.44, resulting in a significant operational cash deficit[21] Shareholder Information - The company reported a total of 32,991 common shareholders at the end of the reporting period[8] - The largest shareholder, HKSCC Nominees Limited, held 22.25% of the shares, totaling approximately 219.29 million shares[8] Product Sales and Market Strategy - The company achieved a commercial drug sales revenue of approximately RMB 892 million, representing a year-on-year growth of about 67.8%[12] - Sales revenue for the drug Toripalimab (brand name: Tuoyi®) reached approximately RMB 668 million, with a year-on-year increase of about 29.7%[12] - The company has not disclosed any new product developments or market expansion strategies in the current report[4] - The company plans to expand the commercialization of Toripalimab with more indications and ongoing clinical research for other products, which is expected to drive revenue growth[12] Inventory and Investments - The company’s inventory increased to approximately RMB 748 million from RMB 599 million at the end of 2022[14] - The company’s long-term equity investments decreased to approximately RMB 442 million from RMB 493 million at the end of 2022[14] - The company’s short-term borrowings were approximately RMB 340 million, slightly down from RMB 351 million at the end of 2022[14] - The company reported an increase in accounts receivable to approximately RMB 366 million, compared to RMB 238 million at the end of 2022[14] Cash and Cash Equivalents - The company’s cash and cash equivalents were approximately RMB 4.17 billion, down from RMB 6.03 billion at the end of 2022[14] - The ending balance of cash and cash equivalents as of Q3 2023 was 4,141,718,242.77, compared to 3,001,414,742.11 at the end of Q3 2022[22] - The total cash and cash equivalents at the beginning of the period were 5,996,935,997.83, indicating a strong liquidity position despite the net decrease in cash[22]

证券代码：688180 证券简称：君实生物 公告编号：临 2023-069 上海君实生物医药科技股份有限公司 2018 年股权激励方案第一个行权期 行权限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次上市流通的限售股股份数量为 1,219,500 股，占公司总股本比例为 0.12%，限售期为自行权之日起三年。 本次上市流通日期为 2023 年 11 月 2 日。 一、本次上市流通的限售股类型 本次上市流通的限售股为上海君实生物医药科技股份有限公司（以下简称 "公司"）2018 年股权激励方案第一个行权期行权形成，本次上市流通的限售 股股份数量为 1,219,500 股，占截至本公告披露日公司总股本 0.12%，限售期为 自行权之日起三年，涉及限售股股东 203 名。该部分限售股将于 2023 年 11 月 2 日起上市流通。 二、本次上市流通的限售股形成后至今公司股本数量变化情况 （一）2018 年股权激励方案股份行权 本次上市流通的限售股形成后至今，因公司实施 2018 年股权激励 ...

海通证券股份有限公司 关于上海君实生物医药科技股份有限公司 2018年股权激励方案第一个行权期 行权限售股上市流通的核查意见 海通证券股份有限公司（以下简称"海通证券"或"保荐机构"）作为上海 君实生物医药科技股份有限公司（以下简称"君实生物"或"公司"）首次公开 发行股票并在科创板上市及2022年向特定对象发行A股股票的持续督导保荐机 构，根据《中华人民共和国公司法》《中华人民共和国证券法》《证券发行上市 保荐业务管理办法》《上海证券交易所科创板股票上市规则》《上海证券交易所科 创板上市公司自律监管指引第1号——规范运作》等有关规定，对公司2018年股 权激励方案第一个行权期行权限售股上市流通的情况进行了核查，核查情况如下： 一、本次上市流通的限售股类型 本次上市流通的限售股为上海君实生物医药科技股份有限公司 2018 年股权 激励方案第一个行权期行权形成，本次上市流通的限售股股份数量为 1,219,500 股，占截至本核查意见披露日公司总股本 0.12%，限售期为自行权之日起三年， 涉及限售股股东 203 名。该部分限售股将于 2023 年 11 月 2 日起上市流通。 二、本次上市流通的限售股形成后至今 ...

本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2023 年 10 月 20 日 （二） 股东大会召开的地点：上海市浦东新区平家桥路 100 弄 6 号 7 幢 15 层 证券代码：688180 证券简称：君实生物 公告编号：临 2023-067 上海君实生物医药科技股份有限公司 2023 年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 50 | | --- | --- | | 其中：A 股股东人数 | 49 | | 境外上市外资股（H 股）股东人数 | 1 | | 2、出席会议的股东所持有的表决权数量 | 329,239,750 | | 其中：A 股股东所持有表决权数量 | 262,682,614 | | 境外上市外资股（H 股）股东所持有表决权数量 | 66,557,136 | | 3、出席会议的股东所持 ...